Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan Long-term Extension in PAH (SERAPHIN OL)
NCT00667823Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Oct 2008
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 36
01
Overview
Phase 3, open-label, single-arm trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Treatment Emergent Adverse Events up to 12 years, Death up to 12 years and 4 more. Started Oct 2008; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00667823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667823.